Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis.

Dr. Michael G. Kharas is an Investigator that leads a laboratory in the Molecular Pharmacology Program at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA) and Professor at Weill Cornell Pharmacology Graduate Program.

Serine synthesis pathway flux is essential for acute myeloid leukemia cells to proliferate in fructose-rich conditions. Jeong S, Savino AM, Chirayil R, Cheng Y, Barin E, Park SM, Schurer A, Mullarky E, Cantley LC, Kharas MG*, Keshari KR*. Cell Metab. 5 January 2021, Pages 145-159.

The Kharas lab is working to identify critical pathways in both normal and leukemic hematopoietic cells. The world of RNA regulators in stem cell biology and their potential as therapeutic …

Kharas has received recognition including the Leukemia Lymphoma Society Scholar Award and American Society of Hematology Scholar Award. His laboratory is developing inhibitors that block the function of RNA regulators as a new therapeutic strategy in leukemia.

Cancer biologist Michael Kharas studies RNA regulators of self-renewal in both normal and leukemic hematopoiesis. As a Research Technician you will perform research activities in collaboration with internal/external personnel to complete science-based projects.

‪Memorial Sloan Kettering‬ - ‪‪Cited by 9,335‬‬ - ‪Leukemia‬ - ‪myeloid leukemia‬ - ‪Hematopoietic stem cells‬ - ‪RNA binding proteins‬ - ‪stem cells‬

Nov 4, 2020 · Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16:903–8.

Michael KHARAS, Professor (Associate) | Cited by 6,985 | of Memorial Sloan Kettering Cancer Center, New York City (MSKCC) | Read 172 publications | Contact Michael KHARAS

Dysregulated Stem Cell Markers Musashi-1 and Musashi-2 are Associated with Therapy Resistance in Inflammatory Breast Cancer.